TOP 5 MOST VIEWED ARTICLES

RECENT COMMENTS

Azmina: In my personal experience, Medical Oncology teams would love to be able to offer patients concurrent [...]   »Read more

Storme Guy: I agree that false promises or prediction are done in a non correct way. Always, medical oncologist [...]   »Read more

Alex: You use EUS for staging only the smaller tumours. What about using endoscopic mucosal resection for [...]   »Read more

dinha: Please write your comment here   »Read more

headcoverings for chemotherapy: I recently came across your blog and have been reading along. I thought I would leave my first c [...]   »Read more

 

Article type: Drug Watch

Keywords: LifeRaftGroup, compassionate use of drugs, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Dying for a lack of compassion?

Dying for a lack of compassion?

For dying cancer patients who have run out of therapeutic options, getting hold of drugs that are still in trials can offer them a last throw of the dice. Yet many find the system for getting early access to drugs, for so-called ‘compassionate use’, is beset by obstacles and delays. They want a greater sense of urgency…and a greater say.

» Anna Wagstaff


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.